.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists recently developed the HSA-C3 anticancer agent. This bimetallic-centered therapeutic increases efficacy while minimizing toxicity. The compound utilizes human serum albumin (HSA) to deliver a bi-copper(II)-centered thiocarbohydrazone directly to tumors. Moreover, C3 integration into an HSA complex improves its pharmacodynamic profile significantly.
Researchers optimized thiocarbohydrazone compounds to create C3, which shows remarkable cytotoxicity. They successfully mapped the HSA-C3 complex. The agent binds specifically to Lys-199 and His-242 residues in the HSA IIA subdomain. Consequently, the HSA-C3 anticancer agent achieves a 74.20% tumor inhibition rate in vivo. In comparison, C3 alone inhibits only 48.71% of growth. Furthermore, this delivery system enhances targeting and reduces adverse side effects.
The HSA-C3 complex also modulates the tumor microenvironment through dual immune activation. Specifically, it blocks the PD-1/PD-L1 interaction to prevent immune evasion. Additionally, the compound resets tumor-associated macrophages toward the M1 phenotype. This approach induces apoptosis and empowers the immune system. Therefore, patients may benefit from more effective and safer metal-based therapies.
The HSA-C3 complex improves outcomes by utilizing human serum albumin as a targeted carrier. This increases the drug concentration at the tumor site. It also boosts the inhibition rate to 74.20%.
The HSA-C3 complex activates the immune system by blocking the PD-1/PD-L1 interaction. It also shifts tumor-associated macrophages to the M1 phenotype, promoting an active immune response.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for the professional judgment of a healthcare provider. Refer to the latest local and national guidelines for clinical practice.
References
Li S et al. Developing a Multitargeted Anticancer Bi-Copper(II)-Centered Thiocarbohydrazone Agent Based on Lys-199 and His-242 Residues in the IIA Subdomain of Human Serum Albumin. J Med Chem. 2026 Mar 24. doi: 10.1021/acs.jmedchem.6c00360. PMID: 41876397.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HSA-C3 complex, a novel bi-copper agent, achieves 74.20% tumor inhibition by targeting human serum albumin and modulating the immune microenvironment....
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
